晚期非小细胞肺癌血管正常化时化疗的临床观察  

Chemotherapy on vascular normalization in patients of advanced non-small cell lung cancer

作　　者：聂学诚[1] 种道群[1] 邱泗安 袁蕾蕾[1] 孔令东 康宝金 汤良[1] 张宾[1] 李瑞[1] 

机构地区：[1]济宁第一人民医院肿瘤科,山东济宁272111 [2]兖州市中医院肿瘤科,272000 [3]兖矿集团总院肿瘤科,273500 [4]兖州市人民医院肿瘤科,272100

出　　处：《临床肿瘤学杂志》2012年第7期648-651,共4页Chinese Clinical Oncology

摘　　要：目的探讨重组人血管内皮抑制素(恩度)诱导肿瘤血管正常化时联合化疗治疗晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法收集经病理组织学或细胞学确诊的Ⅲ、Ⅳ期NSCLC患者43例,随机分为恩度"窗口期"联合化疗组(A)和恩度同步化疗组(B)。A组21例,具体为:恩度15mg静滴,d1～d14;多西紫杉醇75mg/m2静滴,d5;B组22例,恩度用法同A组,多西紫杉醇75mg/m2静滴,d1。两组均21天为1周期。按照RECIST 1.1和NCI CTC 3.0标准分别评价近期疗效和毒副反应。用Kaplan-Meier法进行生存分析。结果 A、B两组患者的有效率分别为14.2%和9.1%(P=0.63),疾病控制率分别为57.1%和54.6%(P=0.76),中位无进展生存期分别为3.7个月和3.5个月(P=0.19),中位总生存期分别为10.2个月和10.5个月(P=0.77)。两组的主要不良反应表现为脱发、血液学毒性和乏力,差异无统计学意义。结论恩度"窗口期"联合化疗与恩度同步化疗治疗NSCLC在有效率、生存期和不良反应方面未见明显差异。Objective To investigate the efficacy and safty of rh-endostatin（endostar） combined with chemotherapy at the stage of vascular normalization on advanced non-small cell lung cancer（NSCLC） patients.Methods Forty-three stage Ⅲ-Ⅳ NSCLC patients confirmed by pathology or cytology were randomized into endostar combined chemotherapy group（A） and endostar concurrent chemotherapy group（B）.Group A contained 21 patients： endostar 15mg iv d1-d14,docetaxel 75mg/m2 iv d5;B group（22 patients） had the same administration of endostar,while doceaxel（75mg/m2） was intravenously dropped on d1.The regimen of the both groups was repeated every 21 days.The efficacy was evaluated strictly after 2 cycles according to RECIST 1.1 criteria.Side effect was evaluated after 1 cycle according to NCI-CTC 3.0 version criteria.Survival analysis was evaluated by Kaplan-Meier method.Results The response rates in A and B groups were 14.2% and 9.1%,respectively（P=0.63）,and the disease control rates in these two groups were 57.1% and 54.6%,respectively（P=0.76）.The median overall survival in A group and B group were 10.2 and 10.5 months,respectively（P=0.77）.The median progression-free survival between the two groups was similar（3.7 vs.3.5 months,P=0.19）.The main side effects were alopecia,hematologic toxicities and weakness in the both two groups and without significance between them.Conclusion The windows period of vascular normalization of endostar in combination with chemotherapy and concurrent chemotherapy showed similar efficacy,survival and side effect.

关 键 词：晚期非小细胞肺癌 重组人血管内皮抑制素/恩度 化学治疗 血管正常化 

分 类 号：R734.2[医药卫生—肿瘤]